Fundraising Fox
Atomwise
San Francisco, US · Founded 2015 · Delaware corporation · 14 employees on LinkedIn · 14 known investors
Find your way into Atomwise
Each arrow is one introduction. Sign up to fill in the first one.
Ask Jeff Thompson to introduce you to Yan Zhao
You →Jeff · together at Towerstream →Yan
Sign up to find every way you can get introduced to Atomwise
- Your email: who you already know at Atomwise, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Atomwise team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Atomwise uses artificial intelligence and machine learning to discover novel small-molecule drugs, with a current focus on developing treatments for immune and inflammatory diseases.
Also known as Atomwise, Inc.
Founders & leadership
Atomwise was founded in 2015 by Izhar Wallach and Abraham Heifets.
Board
Investors · 14
How we know: Aurum Venture Partners's portfolio page · Not right? Tell us
.jpeg){kind=logo}
How we know: B Capital Group's portfolio page · Not right? Tell us
How we know: Cerity Partners Ventures's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Draper Associates's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Unruly Capital's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements$238.6M disclosed across 4 of 6 rounds · 2018–2026
▶$19.8MraisedMar 2026 · 5 investors · BiotechnologyRule 506(b)
- Stephen WorlandExecutive Officer, Director
- Adam SeabrookDirector
- Izhar WallachDirector
- Yan ZhaoExecutive Officer
- Mike VarneyDirector
- Robert MittendorffDirector
- Linda MaxwellDirector
- Offering amount
- $35M
- Amount sold
- $19.8M
- First sale
- Mar 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$44.3MraisedMar 2025 · 19 investors · BiotechnologyRule 506(b)
- Robert MittendorffDirector
- Adam SeabrookDirector
- Linda MaxwellDirector
- Mike VarneyDirector
- Izhar WallachExecutive Officer, Director
- Yan ZhaoExecutive Officer
- Stephen WorlandExecutive Officer, Director
- Offering amount
- $50M
- Amount sold
- $44.3M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$123MraisedAug 2020 · 25 investors · BiotechnologyRule 506(b)
- Izhar WallachExecutive Officer, Director
- Raj GangulyDirector
- Abraham HeifetsExecutive Officer, Director
- Matt OckoDirector
- Han LimExecutive Officer
- Offering amount
- $127M
- Amount sold
- $123M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$51.5MraisedJul 2018 · 31 investors · BiotechnologyRule 506(b)
- Gavin TeoDirector
- Matt OckoDirector
- Kiersten SteadDirector
- Izhar WallachExecutive Officer, Director, Promoter
- Abraham HeifetsExecutive Officer, Director, Promoter
- Offering amount
- $51.5M
- Amount sold
- $51.5M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Atomwise, Inc. is a San Francisco-based drug discovery company that uses deep learning to find novel small molecules. Its platform, described on the company's site as an AI "superplatform," is used to search large regions of chemical space for drug-like molecules and to predict small-molecule binding affinity for protein targets. Its AI system, AtomNet, is described as built for drug discovery and as covering more than 16 billion molecules available for virtual screening.
The company runs an internal pipeline in addition to external work. Programs generated from its platform are positioned as having first- and best-in-class potential in immune and inflammatory diseases. Its discovery portfolio is described as combining an internally developed pipeline with joint ventures and academic and biopharma development partnerships. The company is classified across pharmaceuticals, biotechnology, drug discovery technologies and artificial intelligence sectors.
Founding story
Third-party profiles describe Atomwise as co-founded by Abraham Heifets (CEO), Izhar Wallach (CTO) and Alexander Levy (COO), with a founding date reported as 2012 by some sources.
Business model
Atomwise combines internal drug development with partnered discovery work: it applies its machine-learning platform to targets on behalf of pharmaceutical and agrochemical companies and academic collaborators, and also advances its own pipeline of small-molecule programs, including through joint ventures.
Traction
Described as performing hundreds of projects per year and working with more than 200 universities and hospitals across 40 countries; named partners include BridgeBio, Hansoh, Tulane University, Lilly, Bayer and AbbVie.
Latest developments
The company's site highlights an internal program portfolio in immune and inflammatory diseases generated from its machine-learning platform.
▸Full profile — market position, technology, go-to-market, geography
Market position
Positioned within the AI-for-drug-discovery segment, running hundreds of discovery projects per year with pharmaceutical, agrochemical and academic partners, and backed by institutional and strategic investors.
Technology
Deep learning algorithms for structure-based small-molecule drug discovery, run on high-performance/supercomputing hardware. The AtomNet platform performs virtual screening across a library described as containing more than 16 billion molecules and predicts small-molecule binding affinity.
Go-to-market
Partnership-led: paid and collaborative discovery projects with pharmaceutical and agrochemical companies, joint ventures, and screening collaborations with universities and hospitals, alongside internal program development.
Large pharmaceutical and agrochemical companies, biopharma development partners, and academic and hospital research groups; the company is described as working with more than 200 universities and hospitals in 40 countries.
Geography
Headquartered in San Francisco, California, United States, with academic and hospital collaborations spanning 40 countries.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Related companies · 6
Companies working in the same space as Atomwise.
Legal entities · 1
corporate structureIn the news
▸Research sources · 6
primary sources listed
- Atomwiseatomwise.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Atomwise do?
- Atomwise applies machine learning to structure-based small-molecule drug discovery, focused on immune and inflammatory diseases.
- Who founded Atomwise?
- Atomwise was founded by Izhar Wallach, Abraham Heifets in 2015.
- Who are Atomwise's investors?
- Atomwise's investors include Aurum Venture Partners, B Capital Group, Cerity Partners Ventures, Creative Destruction Lab (CDL), Draper Associates, Mission and Market, Threshold Ventures, Unruly Capital and 6 more.
- How much funding has Atomwise raised?
- Atomwise has disclosed $238.6M raised across 4 of its 6 known rounds.
- Where is Atomwise headquartered?
- Atomwise is headquartered in San Francisco, US.